Ali Naderi

Academic Positions at The University of Queensland

Location:
St Lucia, Brisbane, Queensland, Australia
Company:
The University of Queensland
HQ Phone:
+61 7 3365 1111
Wrong Ali Naderi?

Last Updated 11/30/2017

General Information

Employment History

Academic Positions  - University of Iowa

Associate Professor and Principal Investigator  - University of Hawaii

Clinician - Scientist  - University of Cambridge

Education

MD  - 

Affiliations

Associate Member  - University of Hawaii Cancer Center

Research Fellow and Medical Oncologist  - Princess Alexandra Hospital

Research Fellow and Medical Oncologist  - Molecular Oncogenesis Group

Web References  

Faculty

Ali Naderi, MD, CCST (UK)
Associate Researcher (Associate Professor)

Read More
Ali Naderi, MD, CCST(UK)

Ali Naderi, MD, CCST(UK)
Ali Naderi, MD, CCST (UK) \n This e-mail address is being protected from spambots. You need JavaScript enabled to view it. " _mce_href="mailto: This e-mail address is being protected from spambots. You need JavaScript enabled to view it. "> This e-mail address is being protected from spambots. You need JavaScript enabled to view it. | (808) 584-3999 Ali Naderi, MD, CCST(UK) Associate Researcher (Associate Professor) Clinical and Translational Research University of Hawaii Cancer Center Dr. Naderi is a physician-scientist and medical oncologist with a focus on breast cancer research. He joined the University of Hawaii Cancer Center in January 2016 and previously held faculty positions at the University of Iowa and the University of Queensland. Dr. Naderi currently has research projects to study the molecular functions of Prolactin-Induced Protein (PIP) and Androgen Receptor (AR) in breast cancer. In addition, Dr. Naderi's group is interested in the field of pharmacometabolomics for anti-cancer therapies. PIP also known as GCDFP-15 is one of the most abundant proteins expressed in breast cancer and is used as a characteristic biomarker in the diagnosis of this disease. Dr. Naderi's laboratory has demonstrated that PIP has a significant function in the cell cycle progression of breast cancer cells and his group currently studies the molecular mechanisms of PIP function and translational applications of this widely expressed protein in breast cancer. Furthermore, Dr. Naderi's laboratory was one of the first to identify the role of AR signaling in Estrogen Receptor-negative tumors and contributed to the characterization of "molecular apocrine" subtype of breast cancer using functional and genomic studies. In this respect, Dr. Naderi's group currently studies the molecular functions and novel target genes of AR in breast cancer and investigates the therapeutic implications of AR inhibition in the management of breast cancer patients. Naderi A, Vanneste M. (2014). Prolactin-Induced Protein is required for Cell Cycle Progression in Breast Cancer. Neoplasia,16(4): 329-342.e14. Naderi A, Meyer M. (2012). Naderi A, Meyer M, Dowhan DH. (2012). Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia, 14(4): 283-296. Naderi A, Liu J, Francis GD. (2012). A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. International Journal of Cancer, 130(1): 71-82.

Read More
Ali Naderi, MD, CCST(UK)

Ali Naderi, MD, CCST(UK)
Ali Naderi, MD, CCST (UK) \n This e-mail address is being protected from spambots. You need JavaScript enabled to view it. " _mce_href="mailto: This e-mail address is being protected from spambots. You need JavaScript enabled to view it. "> This e-mail address is being protected from spambots. You need JavaScript enabled to view it. | (808) 441-7718 Ali Naderi, MD, CCST(UK) Associate Member Cancer Biology Program University of Hawaii Cancer Center Dr. Naderi is a physician-scientist and medical oncologist with a focus on breast cancer research. Dr. Naderi joined the University of Hawaii Cancer Center in January 2016 and previously held academic positions at the University of Iowa and University of Queensland. Dr. Naderi currently has research projects to study the molecular functions of Androgen Receptor (AR) and Prolactin-Induced Protein (PIP). PIP is one of the most abundant proteins expressed in breast cancer and is used as a characteristic biomarker in the diagnosis of this disease. Dr. Naderi's laboratory has demonstrated that PIP has a significant function in the cell cycle progression of breast cancer cells and his group currently studies the molecular mechanisms of PIP function and translational applications of this widely expressed protein in breast cancer. Furthermore, Dr. Naderi's laboratory was one of the first to identify the role of AR signaling in Estrogen Receptor-negative tumors and contributed to the characterization of "molecular apocrine" subtype of breast cancer using functional and genomic studies. In this respect, Dr. Naderi's group currently studies the AR transcriptional network to discover novel AR target genes and coregulators in breast cancer. Dr. Naderi is also interested in the therapeutic implications of AR inhibition in the management of breast cancer patients. Naderi A, Vanneste M. (2014). Prolactin-Induced Protein is required for Cell Cycle Progression in Breast Cancer. Neoplasia,16(4): 329-342.e14. Naderi A, Meyer M. (2012). Naderi A, Meyer M, Dowhan DH. (2012). Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia, 14(4): 283-296. Naderi A, Liu J, Francis GD. (2012). A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. International Journal of Cancer, 130(1): 71-82.

Read More

Browse ZoomInfo’s Directories